Pidala, J., Roman-Diaz, J., Kim, J., Nishihori, T., Perkins, J., Tate, C., . . . Kharfan-Dabaja, M. A. (2011). Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. Int J Hematol.
استشهاد بنمط شيكاغوPidala, Joseph, et al. "Targeted IV Busulfan and Fludarabine Followed By Post-allogeneic Hematopoietic Cell Transplantation Rituximab Demonstrate Encouraging Activity in CD20+ Lymphoid Malignancies Without Increased Risk of Infectious Complications." Int J Hematol 2011.
MLA استشهادPidala, Joseph, et al. "Targeted IV Busulfan and Fludarabine Followed By Post-allogeneic Hematopoietic Cell Transplantation Rituximab Demonstrate Encouraging Activity in CD20+ Lymphoid Malignancies Without Increased Risk of Infectious Complications." Int J Hematol 2011.